Company
Incyte
5 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers; 2 in phase 3.
Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.
Biomarkers
Drugs in these trials
Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).
INCB161734 2cetuximab 2rituximab 1pemigatinib 1retifanlimab 1
Trials
5 of 25 trials shown
-
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation
KRAS G12DSolid Tumors
-
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
TafasitamabLenalidomiderituximabcyclophosphamidedoxorubicinvincristineprednisoneTafasitamab placeboLenalidomide placebo
Anaplastic lymphoma kinase (ALK)-positive large BCL
ALK fusionDiffuse Large B-cell Lymphoma
-
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
pemigatinib FDA EU
Documented FGFR2 fusion or rearrangement
FGFR2 fusion or rearrangementUnresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma
-
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB186748cetuximabGEMNabPmFOLFIRINOX
Locally advanced or metastatic solid tumor with KRAS G12D mutation.
KRAS G12DSolid Tumors
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734cetuximabretifanlimabGEMNabPmFOLFIRINOXFOLFOXFOLFIRIINCA33890
Locally advanced or metastatic solid tumor with KRAS G12D mutation.
KRAS G12DSolid Tumors
-
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
pemigatinib FDA EUgemcitabinecisplatin
Documented FGFR2 rearrangement.
FGFR2 fusion or rearrangementUnresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
-
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
INCB099280
Advanced or metastatic microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) (as determined by an approved assay) solid tumors an…
MSI-H / dMMRAdvanced Solid Tumor
-
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Documentation of an actionable FGFR1-3 gene mutation or fusion/rearrangement from tissue : FGFR1-3 fusions or other rearrangements (FGFR1-3 in…
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementGlioblastoma, Adult-type Diffuse Gliomas
-
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Documentation of known/likely actionable known or likely FGFR1-3 alterations.
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementNon-Small Cell Lung Cancer (NSCLC)
-
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
retifanlimabepacadostatpemigatinibINCAGN02385INCAGN02390
Group A only: Tumor tissue tested as MSI-High
MSI-H / dMMREndometrial Cancer
-
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
pemigatinibpembrolizumabgemcitabinecarboplatin
Known FGFR3 mutation or rearrangement confirmed by the central laboratory prior to randomization.
FGFR3 alteration (mutation or fusion)Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
-
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Documentation of an FGFR1-3 gene mutation or translocation.
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementAdvanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations
-
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Documentation of an FGFR1-3 gene mutation or translocation.
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementSolid Tumor Malignancy
-
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgical…
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementUC (Urothelial Cancer)
-
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
pemigatinib FDA EU
…Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)
FGFR2 fusion or rearrangementCholangiocarcinoma
-
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Itacitinibosimertinib FDA EU
Documented evidence of somatic activating mutation in EGFR (eg, G719X, exon 19 deletion, L858R, L861Q) in a tumor tissue sample.
EGFR exon 19 deletion / L858RLung Cancer
-
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
pemigatinibgemcitabinepembrolizumabdocetaxeltrastuzumabretifanlimabcisplatin
A subject's fibroblast growth factor (FGF) or fibroblast growth factor receptor (FGFR) alteration may be based on local or central laboratory results.
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementLung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
-
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Itacitiniberlotinib FDA EU
Documented evidence of an activating mutation in EGFR in tumor samples (exon 19 deletions or point mutation L858R in exon 21 or point mutations at codon 719).
EGFR exon 19 deletion / L858RSolid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
-
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
pembrolizumab FDA EUINCB024360
…elanoma, NSCLC, transitional cell carcinoma of the GU tract, TNBC, SCCHN, ovarian cancer, MSI high colorectal cancer (CRC), RCC, gastric cancer, HCC and DLBCL (Phase 2).
MSI-H / dMMRMicrosatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
-
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
INCB099280adagrasib FDA EU
KRASG12C-mutated solid malignancy determined by a sponsor-approved assay using either tumor tissue…
KRAS G12CAdvanced Solid Tumors
-
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
ipilimumab FDA EU
MSI-H or dMMR metastatic CRC and able to provide fresh or archival tumor tissue for central con…
MSI-H / dMMRMelanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H)
-
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
INCAGN02385
Participants with advanced or metastatic cervical cancer, MSI-high endometrial cancer, gastric cancer (including stomach and GEJ), esophageal cancer, hepato…
MSI-H / dMMRCervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
-
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
INCB086550
Part 3 MSI-H or dMMR Expansion Cohort only (Enrolled ex-United States only): Participants with any MSI…
MSI-H / dMMRSolid Tumors
-
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
…jects enrolled at a lower dose level expansion cohort are required to have documented FGF/FGFR alterations and baseline and on-treatment tumor biopsy for testing of biomarkers.
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementSolid Tumors
-
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
Patients enrolled to Cohort H (endometrial cancer 500 mg Q4W) must have MSI-H or dMMR endometrial cancer, as determined by a local laboratory using IHC or PCR methods …
MSI-H / dMMRLocally Advanced Solid Tumors, Metastatic Solid Tumors
No trials match these filters.